Observational Study of Pediatric Rheumatic Diseases: The CARRA Registry


About this study

Continuation of the CARRA Registry as described in the protocol will support data collection on patients with pediatric-onset rheumatic diseases. The CARRA Registry will form the basis for future CARRA studies. In particular, this observational registry will be used to answer pressing questions about therapeutics used to treat pediatric rheumatic diseases, including safety questions.

Participation eligibility

Participant eligibility includes age, gender, type and stage of disease, and previous treatments or health concerns. Guidelines differ from study to study, and identify who can or cannot participate. There is no guarantee that every individual who qualifies and wants to participate in a trial will be enrolled. Contact the study team to discuss study eligibility and potential participation.

Inclusion Criteria:

  • Onset of rheumatic disease prior to age 16 years for JIA and onset prior to age 19 years for all other rheumatic diseases.
  • Subject (and/or parent/legal guardian when required) is able to provide written informed consent and willing to comply with study procedures.
  • Subject and/or parent/legal guardian can read either English or Spanish.
  • Subject and/or parent/legal guardian is willing to be contacted in the future by study staff.

Exclusion Criteria:

  • Greater than 21 years of age at the time of enrollment.

Participating Mayo Clinic locations

Study statuses change often. Please contact the study team for the most up-to-date information regarding possible participation.

Mayo Clinic Location Status Contact

Rochester, Minn.

Mayo Clinic principal investigator

Matthew Basiaga, D.O.

Open for enrollment

Contact information:

Noelle Drapeau

(507) 266-6397


More information


Publications are currently not available